Takafumi Koyama
YOU?
Author Swipe
View article: PATH-22. Characteristics of various comprehensive genomic profiling tests for central nervous system tumors in Japan since 2023
PATH-22. Characteristics of various comprehensive genomic profiling tests for central nervous system tumors in Japan since 2023 Open
BACKGROUND In Japan, two cancer gene panel (CGP) tests—OncoGuide™ NCC Oncopanel System (NCCG) and FoundationOne® CDx (F1)—were first covered by public insurance in June 2019 and are widely used to identify actionable genetic alterations in…
View article: PATH-34. Assessment of BRAF alterations and recommended treatments in CNS tumors with BRAF alterations
PATH-34. Assessment of BRAF alterations and recommended treatments in CNS tumors with BRAF alterations Open
BACKGROUND Comprehensive genomic profiling (CGP) has been reimbursed in Japan since June 2019, enabling treatment decisions based on genetic alterations. However, only 10–15% of patients receive genomically matched therapy, and its clinica…
View article: Real‐World Comparison of Gene‐Matched vs. Non‐Gene‐Matched Therapy Outcomes Using Integrated Genomic and Clinical Data
Real‐World Comparison of Gene‐Matched vs. Non‐Gene‐Matched Therapy Outcomes Using Integrated Genomic and Clinical Data Open
Previous studies have demonstrated that 10%–25% of patients receive gene‐matched therapy (GMT) after comprehensive genomic profiling (CGP). However, its real‐world clinical effects remain unclear. This study assessed the feasibility of int…
View article: Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends
Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends Open
Chimeric antigen receptor (CAR)-T and T-cell receptor (TCR)-engineered T-cell (TCR-T) therapies have revolutionized the treatment of hematological malignancies; however, their application to solid tumors remains a formidable challenge. The…
View article: A germline and somatic mutation sorting (GeMSort) algorithm for extracting presumed germline pathogenic variants in liquid genomic profiling: Insights from Database of Center for Cancer Genomics and Advanced Therapeutics (C-CAT)
A germline and somatic mutation sorting (GeMSort) algorithm for extracting presumed germline pathogenic variants in liquid genomic profiling: Insights from Database of Center for Cancer Genomics and Advanced Therapeutics (C-CAT) Open
Liquid biopsy comprehensive genomic profiling (LB-CGP) testing is performed on circulating tumor DNA to detect tumor recurrence, predict prognosis, and select therapeutic agents. Pathogenic variants of germline origin in genes associated w…
View article: Biochemical Characterization of a Non-G4-Type RNA Aptamer That Lights Up a GFP-like Fluorogenic Ligand
Biochemical Characterization of a Non-G4-Type RNA Aptamer That Lights Up a GFP-like Fluorogenic Ligand Open
The 17-3 RNA aptamer recognizes DMHBI and induces its fluorescence. We showed that the 17-3 RNA aptamer predominantly induced emission of the phenolate form of DMHBI. We also demonstrated that the active structure of the minimal form of th…
View article: Supplementary Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Table 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Table S1 shows the adverse events that could be considered dose-limiting toxicities.
View article: Supplementary Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Table 3 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Table S3 shows the representativeness of study participants.
View article: Supplementary Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Table 4 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Table S4 shows the duration of treatment and dose.
View article: Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Figure 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Figure S2 shows the study progression and dose steps.
View article: Supplementary Table 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Table 2 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Table S2 shows the prior treatment regimens in the individual study participants.
View article: Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Figure 1 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Figure S1 shows the study design.
View article: Supplementary Table 6 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Table 6 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Table S6 shows the biomarker expression status at baseline.
View article: Supplementary Table 5 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors
Supplementary Table 5 from Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors Open
Table S5 shows the adverse events by primary system-organ-class and preferred term, overall and those of Grade ≥3 severity.
View article: 124P Regional diversity in drug-induced cutaneous adverse reaction among the USA, European Union and Japan
124P Regional diversity in drug-induced cutaneous adverse reaction among the USA, European Union and Japan Open
View article: A Phase I, First‐In‐Human Study of <scp>CBA</scp>‐1205, an Anti‐<scp>DLK1</scp> Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase I, First‐In‐Human Study of <span>CBA</span>‐1205, an Anti‐<span>DLK1</span> Monoclonal Antibody, in Patients With Advanced Solid Tumors Open
CBA‐1205 is a novel humanized antibody targeting delta‐like 1 homolog (DLK1) that enhances antibody‐dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma a…
View article: Current status and future direction of cancer research using artificial intelligence for clinical application
Current status and future direction of cancer research using artificial intelligence for clinical application Open
The expectations for artificial intelligence (AI) technology have increased considerably in recent years, mainly due to the emergence of deep learning. At present, AI technology is being used for various purposes and has brought about chan…
View article: 320 Quantitative clinical pharmacology and mechanistic modeling of TAK-102, a GPC3 targeted CAR-T therapy armored with IL-7 and CCL19, in a phase-1 clinical trial in solid tumor patients
320 Quantitative clinical pharmacology and mechanistic modeling of TAK-102, a GPC3 targeted CAR-T therapy armored with IL-7 and CCL19, in a phase-1 clinical trial in solid tumor patients Open
View article: Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database
Comprehensive Genomic Assessment of Advanced-Stage GI Stromal Tumors Using the Japanese National Center for Cancer Genomics and Advanced Therapeutics Database Open
PURPOSE Clinical utility of comprehensive genomic profiling (CGP) for precision medicine has become evident. Although there are several reports on the genomic landscape of GI stromal tumors (GISTs), large-scale data specific to GIST are li…
View article: Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan
Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan Open
Background Drug-induced lung disease (DILD) is a considerable and potentially fatal adverse event with poorly understood risk factors. Large-scale, data-driven analyses investigating regional discrepancies in DILD incidence are lacking. Th…
View article: Supplementary Figure S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
MASTER KEY PROJECT
View article: Supplementary Figure S5 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S5 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Correlation between the MDM2 copy number and tumor shrinkage
View article: Supplementary Table S5A from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S5A from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Whole-exome sequencing and RNA sequencing analyses of archived tumor tissue samples
View article: Supplementary Figure S4B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Figure S4B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Anti-tumor activity
View article: Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment
View article: Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S5B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment
View article: Supplementary Table S2 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S2 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Patient characteristics
View article: Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Representativeness of study participant
View article: Supplementary Table S7 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S7 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Criteria for modifying treatment
View article: Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study Open
Representativeness of study participant